Population attributable risk of a competing-risk model for breast cancer and non-breast cancer death among women ≥ 65 years.

IF 3 3区 医学 Q2 ONCOLOGY Breast Cancer Research and Treatment Pub Date : 2025-06-01 Epub Date: 2025-03-25 DOI:10.1007/s10549-025-07683-w
Mara A Schonberg, Emily A Wolfson, A Heather Eliassen, Bernard A Rosner, Andrea Z LaCroix, Rebecca A Nelson, Rowan T Chlebowski, Long H Ngo
{"title":"Population attributable risk of a competing-risk model for breast cancer and non-breast cancer death among women ≥ 65 years.","authors":"Mara A Schonberg, Emily A Wolfson, A Heather Eliassen, Bernard A Rosner, Andrea Z LaCroix, Rebecca A Nelson, Rowan T Chlebowski, Long H Ngo","doi":"10.1007/s10549-025-07683-w","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To inform decision making around mammography-screening frequency and cessation, we previously used Fine-Gray competing-risk regression to develop and validate a model to estimate older women's 10-year risk of breast cancer and their competing risk of non-breast cancer (non-BC) death. Here, we aimed to understand the amount of incident breast cancer and non-BC death risk explained by our model among women ≥ 65y.</p><p><strong>Methods: </strong>We included women ≥ 65y who completed the 2004 Nurses' Health Study questionnaire (NHS, n = 59,662) or who participated in the Women's Health Initiative-Extension Study (WHI-ES, n = 82,528). We calculated our model's full and risk factor-specific population attributable risk (PAR%) for incident breast cancer and non-BC death.</p><p><strong>Results: </strong>Mean age of the NHS participants was 73.5y (SD 5.2); 3.1% were diagnosed with breast cancer and 26.1% experienced non-BC death within 10 years. Mean age of WHI-ES participants was 73.6y (SD 5.4); 4.2% were diagnosed with breast cancer and 17.7% experienced non-BC death within 10 years. The full-model PAR% for breast cancer was 58.8% (22.7-80.6) in NHS and 54.8% (24.8-75.2%) in WHI-ES. Modifiable risk factors explained approximately 1/3 of breast cancer risk; BMI ≥ 30 had a PAR% of 6.5% (3.1-9.9%) in NHS and 12.2% (8.5-16.0%) in WHI-ES. For non-BC death, the full-model PAR% was 94.2% (91.4-96.1%) in NHS and 86.2% (80.9-90.0%) in WHI-ES.</p><p><strong>Conclusions: </strong>Our competing-risk model explained the majority of breast cancers and non-BC deaths in women ≥ 65y, and we identified risk factors (e.g., elevated BMI) that may be targeted to reduce the burden of breast cancer in older women.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"687-698"},"PeriodicalIF":3.0000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12757117/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Cancer Research and Treatment","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10549-025-07683-w","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/25 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: To inform decision making around mammography-screening frequency and cessation, we previously used Fine-Gray competing-risk regression to develop and validate a model to estimate older women's 10-year risk of breast cancer and their competing risk of non-breast cancer (non-BC) death. Here, we aimed to understand the amount of incident breast cancer and non-BC death risk explained by our model among women ≥ 65y.

Methods: We included women ≥ 65y who completed the 2004 Nurses' Health Study questionnaire (NHS, n = 59,662) or who participated in the Women's Health Initiative-Extension Study (WHI-ES, n = 82,528). We calculated our model's full and risk factor-specific population attributable risk (PAR%) for incident breast cancer and non-BC death.

Results: Mean age of the NHS participants was 73.5y (SD 5.2); 3.1% were diagnosed with breast cancer and 26.1% experienced non-BC death within 10 years. Mean age of WHI-ES participants was 73.6y (SD 5.4); 4.2% were diagnosed with breast cancer and 17.7% experienced non-BC death within 10 years. The full-model PAR% for breast cancer was 58.8% (22.7-80.6) in NHS and 54.8% (24.8-75.2%) in WHI-ES. Modifiable risk factors explained approximately 1/3 of breast cancer risk; BMI ≥ 30 had a PAR% of 6.5% (3.1-9.9%) in NHS and 12.2% (8.5-16.0%) in WHI-ES. For non-BC death, the full-model PAR% was 94.2% (91.4-96.1%) in NHS and 86.2% (80.9-90.0%) in WHI-ES.

Conclusions: Our competing-risk model explained the majority of breast cancers and non-BC deaths in women ≥ 65y, and we identified risk factors (e.g., elevated BMI) that may be targeted to reduce the burden of breast cancer in older women.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
≥65岁妇女乳腺癌和非乳腺癌死亡的竞争风险模型的人口归因风险
目的:为了为乳房x光检查频率和戒烟的决策提供信息,我们之前使用了Fine-Gray竞争风险回归来开发和验证一个模型,以估计老年妇女10年乳腺癌风险及其非乳腺癌(non-BC)死亡的竞争风险。在这里,我们的目的是了解我们的模型解释的≥65岁女性中乳腺癌发生率和非bc死亡风险。方法:我们纳入了完成2004年护士健康研究问卷(NHS, n = 59,662)或参加妇女健康倡议-扩展研究(WHI-ES, n = 82,528)的≥65岁的妇女。我们计算了模型中发生乳腺癌和非bc死亡的全部和危险因素特异性人群归因风险(PAR%)。结果:NHS参与者的平均年龄为73.5岁(SD 5.2);3.1%的人被诊断为乳腺癌,26.1%的人在10年内经历了非bc死亡。WHI-ES参与者的平均年龄为73.6岁(SD 5.4);4.2%被诊断为乳腺癌,17.7%在10年内经历非bc死亡。在NHS中,乳腺癌的全模型PAR%为58.8%(22.7-80.6),在WHI-ES中为54.8%(24.8-75.2%)。可改变的风险因素解释了大约1/3的乳腺癌风险;BMI≥30在NHS中PAR%为6.5%(3.1-9.9%),在WHI-ES中PAR%为12.2%(8.5-16.0%)。对于非bc死亡,全模型PAR%在NHS为94.2%(91.4-96.1%),在WHI-ES为86.2%(80.9-90.0%)。结论:我们的竞争风险模型解释了65岁以上女性中大多数乳腺癌和非bc死亡,我们确定了可能减轻老年女性乳腺癌负担的危险因素(例如,BMI升高)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
6.80
自引率
2.60%
发文量
342
审稿时长
1 months
期刊介绍: Breast Cancer Research and Treatment provides the surgeon, radiotherapist, medical oncologist, endocrinologist, epidemiologist, immunologist or cell biologist investigating problems in breast cancer a single forum for communication. The journal creates a "market place" for breast cancer topics which cuts across all the usual lines of disciplines, providing a site for presenting pertinent investigations, and for discussing critical questions relevant to the entire field. It seeks to develop a new focus and new perspectives for all those concerned with breast cancer.
期刊最新文献
Rb expression in metastatic ER-positive breast cancer: implications for precision oncology. Automated calculation of background parenchymal enhancement as a biomarker of treatment responses and recurrence-free survival in breast cancer. Risk of CNS relapse following pathological complete response to neoadjuvant chemotherapy in early breast cancer. House value as an individual socioeconomic indicator for breast cancer survival and late-stage diagnosis: a population-based cohort study from Northern Ireland. Correction to: A Canadian real‑world, multi‑center, prospective, observational study assessing the treatment duration, the treatment sequence, and the overall survival for patients treated with endocrine therapy ± targeted therapy in HR + HER2‑negative advanced breast cancer.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1